ACE-031
Activin Receptor Type IIB Decoy / ActRIIB-Fc
A soluble activin type IIB receptor fused to an antibody Fc domain. It acts as a decoy that traps myostatin, activin, GDF-11 and related ligands. It was developed for Duchenne muscular dystrophy, but that trial was stopped early for nosebleeds and small dilated blood vessels. Not FDA-approved.
Half-life
~10–15 days
Typical Dose
1–3 mg/kg every 2 weeks
1.7999999999999998/3Route
subcutaneous
Category
growth_hormone
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How ACE-031 is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 1–3 mg/kg every 2 weeks. Half-life: ~10–15 days. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
A single 3 mg/kg SubQ dose raised lean mass 3.3% at day 29 in healthy postmenopausal women. In boys with Duchenne muscular dystrophy (24 patients), the trial was stopped early for nosebleeds and small dilated blood vessels, and gains in lean mass and walking distance were not statistically significant. No published study gave it IV.
- Phase 1 study in healthy women (2013)
- Trial in Duchenne muscular dystrophy (2017)
Extremely rare in biohacking community due to cost and availability. Those who have used it report rapid lean mass gains. Bleeding side effects are a real concern. Most biohackers opt for follistatin or other myostatin inhibitors as more accessible alternatives.
- Advanced performance enhancement forums
- Clinical trial participant anecdotal reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for ACE-031 and 90+ other compounds with Pro.
Upgrade to ProSafety & Contraindications
- Bleeding disorders or anticoagulant therapy
- Active cancer (broad growth factor trap)
- Vascular abnormalities
- Pregnancy or breastfeeding
ACE-031: common questions
What is ACE-031?
A soluble activin type IIB receptor fused to an antibody Fc domain. It acts as a decoy that traps myostatin, activin, GDF-11 and related ligands. It was developed for Duchenne muscular dystrophy, but that trial was stopped early for nosebleeds and small dilated blood vessels. Not FDA-approved.
How is ACE-031 dosed?
ACE-031 is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 1–3 mg/kg every 2 weeks. Clinical (human trials): Single SubQ dose of 0.02–3 mg/kg (healthy women); 0.5 mg/kg every 4 weeks or 1 mg/kg every 2 weeks SubQ (boys with DMD); Every 2–4 weeks; 12 weeks planned in DMD; stopped early. Experimental (early or animal data): Variable — no community consensus; Every 2 weeks; Short cycles only due to safety concerns. These ranges describe what has been studied or used; they are not a prescription.
Is ACE-031 FDA-approved?
No. ACE-031 is not approved by the FDA for any use in people.
What is the half-life of ACE-031?
DoseCraft's library lists a half-life of ~10–15 days. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use ACE-031?
Listed contraindications: Bleeding disorders or anticoagulant therapy; Active cancer (broad growth factor trap); Vascular abnormalities; Pregnancy or breastfeeding.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.